2021-10-21| Special

Reimagining the Healthcare System Innovation Ecosystem in Europe, Post-COVID

by Sahana Shankar
Share To
The COVID-19 pandemic transformed the pharma industry in the past two years, accelerating research and dialogue between stakeholders while unraveling significant deficiencies in the public healthcare infrastructure across the globe. At the tail-end of the pandemic, pioneers in healthcare took stock of the innovation, policies, and infrastructure at the Reuters event, Pharma 2021.

The first keynote panel discussion had industry experts look at the future of the healthcare innovation ecosystem in Europe. The panel comprised of 1. Nathalie Moll, Director General of EFPIA, European Federation of Pharmaceutical Industries and Associations 2. Jo De Cock, , Former Administrative General, INAMI, Institut national d'assurance maladie-invalidité, Belgium 3. Meindert Boysen, Director of National Institute of Health and Care Excellence, UK 4. Iskra Reic, Executive VP-AstraZeneca, Europe and Canada

Recounting their key learnings from the pandemic, the panelists shared optimism in incorporating collaboration and flexibility into building the future healthcare infrastructure.

GO Prime with only $1.49 now

OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices
First-Ever Insect Brain Neuron Map Completed
AbbVie Unveils Latest Data For Skyrizi In Difficult-To-Treat Psoriasis
Sanofi Slashes Insulin Prices by Up to 78% Following Hot On the Heels of Major Competitors
Novartis Snags Pediatric Brain Cancer Indication for Oncology Combination Therapy
Pfizer, Astellas’ Prostate Cancer Drug Xtandi Achieves Goals In Phase 3
Scroll to Top